Kestra Medical Technologies earnings release, July 14, 2026

Kestra Medical Technologies, Ltd. (KMTS) · Form 8-K, Item 2.02 · Filed · SEC filing

Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results

KIRKLAND, Wash., July 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the fourth quarter and fiscal year ended April 30, 2026.

Financial Highlights

• Fiscal 4Q26 revenue of $28.6 million, an increase of 66% compared to the prior year period.

• FY26 revenue of $95.1 million, an increase of 59% compared to FY25.

• Fiscal 4Q26 gross margin of 54.8% compared to 44.3% in the prior year period.

• FY26 gross margin of 51.4% compared to 40.5% in FY25.

• FY27 revenue guidance of $137 million, an increase of 44% compared to fiscal year 2026.

“Kestra concluded fiscal year 2026 with another strong quarter of financial performance, generating revenue growth of 66% while expanding gross margin to 55%,” said Brian Webster, President and CEO. “In fiscal year 2026, the ASSURE® system protected 18,000 patients from sudden cardiac arrest, a testament to the dedication of our mission-driven team. We also made significant progress on key operational objectives, including rapid growth of our commercial organization, release of compelling primary results from our FDA post-approval study, launch of our latest algorithm update, fortification of our balance sheet, and entrance into a strategic collaboration with Biobeat Technologies. We remain confident that our focus on innovation and executing on our commitments to prescribers and their patients will continue to drive market expansion and advance Kestra on its path to market leadership.”

Fourth Quarter Fiscal 2026 Financial Results

• Total revenue was $28.6 million, an increase of 66% compared to the prior year period. o

6,357 prescriptions were written for the ASSURE® system, an increase of 63% compared to the prior year period. o

Revenue growth was driven primarily by higher market share and wearable cardioverter defibrillator (WCD) market expansion. Revenue also benefited from a higher mix of in-network patients and improvements in revenue cycle management capabilities.

• Gross profit was $15.7 million compared to $7.6 million in the prior year period. o

Gross margin expanded to 54.8% compared to 44.3% in the prior year period, driven by volume leverage, a higher mix of in-network patients and execution of planned cost improvement programs.

• GAAP operating expenses were $55.0 million compared to $55.8 million in the prior year period. o

Excluding non-recurring costs and share-based compensation expense, adjusted operating expenses

* were $44.7 million compared to $29.7 million in the prior year period. The increase was primarily attributable to growth in expenses related to the company’s accelerated commercial expansion.

• GAAP net loss was $38.8 million compared to GAAP net loss of $51.1 million in the prior year period. o

Adjusted EBITDA

* loss was $26.7 million compared to an adjusted EBITDA loss of $20.3 million in the prior year period.

• Cash and cash equivalents, and investments totaled $262.2 million as of April 30, 2026. o

Net cash used in operating activities was $18.7 million, a reduction from $24.1 million in the prior year period.

Fiscal Year 2026 Financial Results

• Total revenue was $95.1 million, an increase of 59% compared to FY25. o

20,720 prescriptions were written for the ASSURE® system, an increase of 57% compared to FY25.

• Gross profit was $48.9 million compared to $24.2 million in FY25. o

Gross margin expanded to 51.4% compared to 40.5% in FY25.

• GAAP operating expenses were $183.6 million compared to $130.6 million in FY25. o

Excluding non-recurring costs and share-based compensation expense, adjusted operating expenses

* were $144.6 million compared to $100.6 million in FY25.

• GAAP net loss was $131.6 million compared to GAAP net loss of $113.8 million in FY25. o

Adjusted EBITDA

* loss was $87.0 million compared to an adjusted EBITDA loss of $68.4 million in FY25.

*Adjusted operating expenses and adjusted EBITDA are non-GAAP financial measures. See “Use of Non-GAAP Financial Measures” below for additional information. Reconciliations of adjusted operating expenses and adjusted EBITDA to the most directly comparable GAAP measure are included in this press release.

Fiscal Year 2027 Revenue Guidance

Kestra expects revenue of $137 million in FY27, which would represent growth of 44% compared to FY26.

Webcast and Conference Call

Kestra will host a conference call today at 4:30 p.m. Eastern Time to discuss financial results. A live and archived webcast of the event will be available in the “Events” section of the investor relations website.

About Kestra

Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.

Use of Non-GAAP Financial Measures

This press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (“GAAP”), including adjusted operating expense and adjusted EBITDA. The non-GAAP financial measures are provided as supplemental information to Kestra’s financial measures presented in this press release that are calculated and presented in accordance with GAAP.

Adjusted operating expense is calculated as operating expenses, as adjusted to exclude share-based compensation expense and non-recurring expenses. Adjusted EBITDA is calculated as net income (loss), as adjusted to exclude other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense,... (truncated)t believes they will allow investors to view Kestra’s performance in a manner similar to the method used by management to evaluate Kestra’s performance for both strategic and annual operating planning. Management believes that in order to properly understand short-term and long-term financial trends, it is helpful for investors to understand the impact of the items excluded from the calculation of adjusted operating expenses and adjusted EBITDA, in addition to considering Kestra’s GAAP financial measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are not reflective of our ongoing core business operations and financial condition. Excluding such items allows investors and analysts to compare our operating performance to other companies in our industry and to compare our period-over-period results.

The non-GAAP financial measures used by Kestra may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Kestra’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. A reconciliation of adjusted operating expenses and adjusted EBITDA reported in this press release to the most comparable respective GAAP measure for the respective periods appears in the tables captioned “Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses” and “Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA” later in this release. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers.

Financial statements

Income Statement

Three Months Ended April 30, — (unaudited) (in thousands)

Three Months Ended April 30, – 2026Three Months Ended April 30, – 2025Year Ended April 30, – 2026Year Ended April 30, – 2025
Revenue28,63817,23395,12659,815
Cost of revenue12,9569,60046,26335,605
Gross profit15,6827,63348,86324,210
Operating expenses:Research and development5,6345,38619,48415,652
Operating expenses:Selling, general and administrative49,39250,459164,120114,936
Operating expenses:Total operating expenses55,02655,845183,604130,588
Operating expenses:Loss from operations-39,344-48,212-134,741-106,378
Other expense (income):Interest expense1,8441,7607,5467,734
Other expense (income):Interest income-2,226-1,656-8,351-3,199
Other expense (income):Other expense (income)-3192,693-2,6182,766
Other expense (income):Net loss before provision for income taxes-38,643-51,009-131,318-113,679
Other expense (income):Provision for income taxes192102294135
Other expense (income):Net loss-38,835-51,111-131,612-113,814
Other expense (income):Less: Undeclared preferred stock dividends3,29112,321
Other expense (income):Net loss attributable to common shareholders, basic and diluted-38,835-54,402-131,612-126,135
Other expense (income):Net loss per share attributable to common shareholders, basic and diluted-0.67-2.21-2.43-5.13
Other expense (income):Weighted-average shares of common shares outstanding, basic and diluted58,396,69824,583,74554,184,69824,583,745
Other comprehensive loss:Net loss-38,835-51,111-131,612-113,814
Other comprehensive loss:Unrealized loss on marketable securities-218-218
Other comprehensive loss:Comprehensive loss-39,053-51,111-131,830-113,814

Income Statement

Three Months Ended April 30, — (unaudited) (in thousands)

Three Months Ended April 30, – 2026Three Months Ended April 30, – 2025Year Ended April 30, – 2026Year Ended April 30, – 2025
GAAP Net loss-38,835-51,111-131,612-113,814
Non-GAAP Adjustments:Interest expense1,8441,7607,5467,734
Non-GAAP Adjustments:Interest income-2,226-1,656-8,351-3,199
Non-GAAP Adjustments:Other expense (income)-3192,693-2,6182,766
Non-GAAP Adjustments:Provision for income taxes192102294135
Non-GAAP Adjustments:Depreciation expense2,3251,8368,7097,968
Non-GAAP Adjustments:Share-based compensation expense10,30422,31333,64424,271
Non-GAAP Adjustments:Non-recurring expenses3,8095,3965,736
Non-GAAP Adjustments:Adjusted EBITDA-26,715-20,254-86,992-68,403

Balance Sheet

(unaudited) (in thousands)

April 30, – 2026April 30, – 2025
Current assetsCash and cash equivalents99,710237,595
Current assetsShort-term investments96,724
Current assetsAccounts receivable, net14,5428,081
Current assetsDisposable medical equipment supplies6,7066,572
Current assetsPrepaid expenses and other current assets4,6773,080
Current assetsTotal current assets222,359255,328
Current assetsLong-term investments65,767
Current assetsRight-of-use assets3,3642,078
Current assetsDeposits1,7612,021
Current assetsRestricted cash334334
Current assetsProperty and equipment, net59,09034,830
Current assetsOther long-term assets5,7901,153
Current assetsTotal assets358,465295,744
Current liabilitiesAccounts payable27,29523,961
Current liabilitiesAccrued liabilities23,04613,829
Current liabilitiesOperating lease liabilities, current portion31187
Current liabilitiesTotal current liabilities50,37237,977
Current liabilitiesOperating lease liabilities, net of current portion4,1113,026
Current liabilitiesWarrant liabilities1,3698,097
Current liabilitiesOther long-term liabilities306140
Current liabilitiesLong-term debt, net42,64941,098
Current liabilitiesTotal liabilities98,80790,338
Shareholders’ equityCommon Shares, $1.00 par value; 100,000,000 shares authorized as of April 30, 2026 and April 30, 2025; 58,383,924 issued and outstanding as of April 30, 2026 and 51,348,656 shares issued and outstanding as of April 30, 202558,38451,349
Shareholders’ equityAdditional paid-in capital853,353674,306
Shareholders’ equityAccumulated other comprehensive loss-218
Shareholders’ equityAccumulated deficit-651,861-520,249
Shareholders’ equityTotal shareholders’ equity259,658205,406
Shareholders’ equityTotal liabilities and shareholders’ equity358,465295,744

Cash Flow

Year Ended April 30, — (unaudited) (in thousands)

Year Ended April 30, – 2026Year Ended April 30, – 2025
Cash flows from operating activitiesNet loss-131,612-113,814
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization8,7097,968
Adjustments to reconcile net loss to net cash used in operating activities:Loss on disposal of property and equipment1,1611,340
Adjustments to reconcile net loss to net cash used in operating activities:Reserve for equipment and supplies2,435754
Adjustments to reconcile net loss to net cash used in operating activities:Provision for uncollectible accounts receivable2,5962,694
Adjustments to reconcile net loss to net cash used in operating activities:Amortization (accretion) of premiums (discounts) on securities, net-106
Adjustments to reconcile net loss to net cash used in operating activities:Interest paid-in-kind855
Full release

Forward-Looking Statements

Except where otherwise noted, the information contained in this press release is as of July 14, 2026. Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, Kestra undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects; and expectations for our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “continue,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “advance,” “remain,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Kestra’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; risks and uncertainties related to market conditions; and other risks and uncertainties, including those described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended April 30, 2026 and other filings filed or to be filed with the U.S. Securities and Exchange Commission (“SEC”). These filings, when made, are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/.

Investor Relations

Neil Bhalodkar neil.bhalodkar@kestramedical.com

KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Kestra Medical Technologies earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.